Apitoria Pharma Profile
Key Indicators
- Authorised Capital ₹ 100.00 Cr
as on 17-11-2024
- Paid Up Capital ₹ 99.00 Cr
as on 17-11-2024
- Company Age 7 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1,800.00 Cr
as on 17-11-2024
- Revenue %
(FY 2023)
- Profit 17.11%
(FY 2023)
- Ebitda 17.11%
(FY 2023)
- Net Worth -8.80%
(FY 2023)
- Total Assets -8.66%
(FY 2023)
About Apitoria Pharma
The Corporate was formerly known as Auro Pharma India Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 100.00 Cr and a paid-up capital of Rs 99.00 Cr.
The company currently has active open charges totaling ₹1,800.00 Cr.
The Key Managerial Personnel (KMP) at Apitoria Pharma Private Limited India are Sanjay Chaturvedi as Ceo, Srinivas Bodige as Company Secretary, and Brundaban Dash as Cfo. Nityananda Kambam, Santhanam Subramanian, Satakarni Makkapati, and One other member serve as directors at the Company.
- CIN/LLPIN
U24298TG2017PTC121342
- Company No.
121342
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Dec 2017
- Date of AGM
12 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Apitoria Pharma?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Chaturvedi  | CEO | 04-Apr-2023 | Current |
| Srinivas Bodige | Company Secretary | 15-Nov-2024 | Current |
| Brundaban Dash | CFO | 19-Apr-2024 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nityananda Kambam | Director | 20-Dec-2017 | Current |
| Santhanam Subramanian | Director | 09-Feb-2023 | Current |
| Satakarni Makkapati | Director | 23-May-2023 | Current |
| Mylandlahalli Ashwini | Director | 19-Apr-2024 | Current |
Financial Performance of Apitoria Pharma.
Apitoria Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 17.11% increase in profit. The company's net worth dipped by a decrease of 8.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Apitoria Pharma?
In 2023, Apitoria Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aurobindo Pharma LtdActive 38 years 26 daysNityananda Kambam and Satakarni Makkapati are mutual person
- Apl Healthcare LimitedActive 18 years 1 month
Nityananda Kambam and Mylandlahalli Ashwini are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 30 Oct 2023 | ₹1,800.00 Cr | Open |
How Many Employees Work at Apitoria Pharma?
Unlock and access historical data on people associated with Apitoria Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Apitoria Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Apitoria Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
